Download Image
    
Share
  
Post
Beta-glucans for COVID-19
2 studies with 64 patients
Hospital Icon Control
Hospital Icon Beta-glucans Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Beta-glucans studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -49% Mortality -222% RCTs -49% Early -222% Late 0% Favorsbeta-glucans Favorscontrol
Jan 31
 Pushkala et al., Global Advances in Integrative Medicine and Health, doi:10.1177/27536130251327134 Efficient Control of IL-6, CRP and Ferritin in COVID-19 Patients With Two Variants of Beta-1,3-1,6 Glucans in Combination: An Open-Label, Prospective, Randomised Clinical Trial
444% higher ventilation (p=0.2) and 444% higher ICU admission (p=0.2). RCT 40 COVID-19 patients showing significantly decreased IL-6 levels at day 7 with the combination of AFO-202 and N-163 beta-glucans compared to standard treatment, however there were no significant differences in clinical outcomes.
Sep 25
2021
 Raghavan et al., Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2021.112243 Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study
no change in oxygen therapy (p=1) and 12% longer hospitalization. RCT 24 hospitalized COVID-19 patients showing potential benefit with Aureobasidium pullulans beta-glucan supplementation. While inflammatory markers (IL-6, D-dimer) initially decreased in all groups by day 15, they rebounded to abnormal l..